Company

Aeglea BioTherapeutics, Inc.

Headquarters: Austin, TX, United States

Employees: 101

CEO: Dr. Anthony G. Quinn M.D., M.B Ch.B., Ph.D., FRCP

NASDAQ: AGLE

Market Cap

$48.6 Million

USD as of Jan. 1, 2024

Market Cap History

Aeglea BioTherapeutics, Inc. market capitalization over time

Evolution of Aeglea BioTherapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Aeglea BioTherapeutics, Inc.

Detailed Description

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Aeglea BioTherapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: AGLE wb_incandescent

Details

Headquarters:

805 Las Cimas Parkway

Suite 100

Austin, TX 78746

United States

Phone: 512 942 2935

Fax: 512 872 5121